2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

9:00AM-11:00AM: Abstract Number: 803

Interferon-Alpha Mediated Lowering of Pentraxin-3 Levels in Systemic Lupus Erythematosus?

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 287

Interleukin-35 in Idiopathic Inflammatory Myopathies

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 887

Intravenous Immunoglobulin As Immunomodulating Agent in ANCA-Associated Vasculitides: A French Nationwide Study of 92 Patients

Vasculitis Poster I

9:00AM-11:00AM: Abstract Number: 271

Investigating an Auto-Inflammatory Component of COPD That Contributes to Progressive Decline in Lung Function Despite Smoking Cessation

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 517

Investigating Psychological Predictors of Biologic Treatment Response in Patients with Severe Active Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 298

Investigating the Pathogenic Role of ER Stress Pathway Activation in the Idiopathic Inflammatory Myopathies (IIM): Skeletal Muscle Cells As a Source of Cytokines (Myokines)

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 306

Investigating the Pathogenic Role of ER Stress Pathways in the Idiopathic Inflammatory Myopathies (IIM): Interrogating the Role of Micro-RNA 133a As an Important Regulator of ER Stress Activation

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 715

Investigating the Role of Vitamin D in Patients with SLE

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

9:00AM-11:00AM: Abstract Number: 24

Investigating the Role of Vitamin D in the Transition to Systemic Lupus Erythematosus in Individuals at Risk for the Disease

Epidemiology and Public Health Poster I: Comorbidities and Outcomes of Systemic Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 257

Investigation of the Arterial Stiffness and Associated Factors in Patients with Familial Mediterranean Fever

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 647

Involvement of Peripheral Nervous System in Primary Sjögren Syndrome, a Gessar Analysis

Sjögren's Syndrome Poster I: Clinical Insights into Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 695

Is a Geriatric Rheumatology Sub-Group Worth Distinguishing? Disease Characteristics of a Geriatric Psoriatic Arthritis (Gero PsA) Subgroup Compared with Those of below 45 Years of Age

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

9:00AM-11:00AM: Abstract Number: 704

Is Axial Involvement Underestimated in Patients with Psoriatic Arthritis? Data from the Bepas Cohort

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

9:00AM-11:00AM: Abstract Number: 698

Is It Possible to Identify Psoriasis Patients Who Will Develop Axial Disease? Real Life Data from Psart (Psoriatic Arthritis Registry of Turkey)

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

9:00AM-11:00AM: Abstract Number: 437

Is Mode of Action Important When Switching Biologic Monotherapy in Rheumatoid Arthritis? Drug Adherence Results from the Swedish Ssatg Registry

Rheumatoid Arthritis - Clinical Aspects Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].